Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449424 | 0.86 | CYP2C9 (0.56) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13465746 | 0.84 | POLB (0.40) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13449246 | 0.84 | CYP2C9 (0.50) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13466292 | 0.80 | HPGD (0.47) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13449245 | 0.74 | GAA (0.54) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL11499538 | 0.71 | CYP2C9 (0.45) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13275155 | 0.71 | POLB (0.44) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL2361589 | 0.71 | POLB (0.40) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13449431 | 0.69 | CYP2C9 (0.58) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13274726 | 0.69 | POLB (0.42) | CYP2C9KMT2AMEN1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | CYP2C9 4808/4885KMT2A 720/4885MEN1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.